DSIP
Women's HealthWomen's-health applications of DSIP require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Mechanism remains incompletely characterised Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier.. Dosing at 100-500 mcg 1x daily before sleep via subq/intranasal with cycle-phase-aware tracking is the standard protocol for premenopausal users.
Key Takeaways
Female-physiology lens: DSIP response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Mechanism remains incompletely characterised. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 100-500 mcg 1x daily before sleep via subq/intranasal; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Cyclical hormone background shapes how women experience DSIP. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, DSIP is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
Cyclical and hormonal context
Female physiology is cyclical in a way that male physiology is not, and DSIP's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. DSIP's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
In the perimenopausal window, DSIP for bone density produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
PCOS Support is one of the dimensions on which women track DSIP response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
For menopause in female users, DSIP is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
In the perimenopausal window, DSIP for mood (cycle-related) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-500 mcg | 4–6 weeks initial cycle |
| Women's Health focus | SubQ | 100-500 mcg | 1x daily before sleep |
| Maintenance phase | SubQ | 70-500 mcg | Ongoing with periodic pauses |
Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- DSIP + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with DSIP's mechanism in female physiology protocols.
- DSIP + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with DSIP's mechanism in female physiology protocols.
- DSIP + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with DSIP's mechanism in female physiology protocols.
- DSIP + Epithalon: Identified by Khavinson in St. Pairs naturally with DSIP's mechanism in female physiology protocols.
Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.
Lens-specific safety considerations for female physiology use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Can I use DSIP during pregnancy or while trying to conceive?
Is DSIP appropriate during perimenopause?
Can I use DSIP alongside HRT?
Best monitoring labs for female users?
What is DSIP?
How does DSIP interact with female hormonal cycling?
Start a DSIP Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified DSIP and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 848 Da
- Sequence length
- 9 aa
- Half-life
- ~7 min plasma; CNS effects longer
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small human series
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for DSIP
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised